CSL shares on watch after annual R&D update

Shares in CSL Ltd (ASX: CSL) will be on watch this morning after the healthcare group's latest research and development update.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in CSL Limited (ASX: CSL) could be moving in early trade after the company's annual research and development (R&D) update.

What did CSL announce today?

CSL's global R&D footprint now boasts over 1,700 scientists across the UK, Europe, China, Australia and the United States.

The group is collaborating with universities and institutions across the globe as it looks for innovative healthcare solutions.

Total R&D investment sits at 10–11% of global revenue and totalled $832 million in 2018–2019. This is predominantly in New Product Development with smaller allocations to Market Development and Life Cycle Management.

CSL shares could be worth watching this morning following key updates including regulatory approvals.

The healthcare giant continues to rollout its Hizentra product across Russia, Indonesia, Japan, Brazil and Mexico.

There are a number of products across the R&D pipeline, including Afluria QIV and Fluad QIV here in the registration phase here in Australia.

Senior Vice President Dr. Andrew Nash also touched on CSL's new product opportunities. Plasma and Recombinant are 2 key areas for the group while Gene Therapy is also providing opportunities.

CSL shares have rocketed 49.91% higher this year to $277.90 as the group smashed its own ASX record high several times.

New facilities in Australia (Melbourne), Switzerland (Bern) and the United States (Pasadena) are also expanding the group's capabilities.

CSL's R&D pipeline includes funding and collaboration initiatives across the globe as well as venture capital investments. Biotech partnerships with Momenta and strategic partnerships such as its Walter and Eliza Hall Institute alliance are also core.

The group is seeing strong demand across its portfolio including its Immunoglobulin, Coagulation, Specialty and Albumin products.

The group's shares will be worth watching after saying it remains on track to become a market leader in CIDP, a rare neurological disorder.

CSL shares have rocketed higher so far this year and the group's R&D expenditure is key to its success.

Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »